Open in interactive viewer → charts, metric popovers & call review

NextPlat's Turnaround Is a Base Effect — and the ATM It Swore Off Is Already Open

A 35% gross margin and a 65% smaller operating loss look triumphant against a Q3 2025 that management itself called the low point. Sequentially, revenue fell 12% and the loss widened seven-fold.
NXPL · Earnings Call · 2026-11-12

The comparison nobody put on the slide

NextPlat's third quarter is a genuinely better business than it was a year ago — on the income statement line where the year-ago number is worst. Revenue fell to $10.5 million from $13.8 million, yet gross profit rose to $3.7 million from $2.7 million and the operating loss shrank to $0.8 million from $2.2 million. The CEO framed it plainly: “we have generated dramatic improvements across nearly all key financial metrics, most notably in our margins and in the substantial reduction in operating losses” — David Phipps, Chief Executive Officer · 2026-11-12. That is true, and it is also a base effect. The comparison quarter is Q3 2025 — the quarter management told investors, twelve months ago, “we would review Q3 results as the low point in our business” — David Phipps, Executive · 2025-11-13. Beating your own declared trough is a low bar, and the more informative slope is the one inside the current year. The fundamentals block, which still carries the Q2 filing, shows just how good the setup was: total revenue of $12 million in 2026Q2 and an operating margin of -1.1%, nearly breakeven. The CFO did not hide the reversal: “Sequentially, results were softer than the second quarter, and I will walk through the drivers of that” — Amanda Ferrio, Chief Financial Officer · 2026-11-12. So: revenue $12 million to $10.5 million, gross profit $5 million to $3.7 million, operating income from roughly flat to -$0.8 million. The company closed in on its stated 2026 breakeven goal in Q2 and then stepped back from it in Q3. That is the story the year-over-year framing is built to obscure.

340B works. It also concentrates.

The mix shift is real and it is the best thing in the release. Pharmacy contract revenue quadrupled to $2.4 million from $0.6 million, on a $1.6 million increase in 340B volume, as fourteen contracted entities signed this year and worked through HRSA registration and a roughly 90-day onboarding lag. Consolidated gross margin of 35% against nearly 20% a year ago is the payoff. Healthcare segment gross margin hit a little over 41% versus 18%. But the same quarter showed the fragility of that model. One customer permanently closed one of the two medication fulfillment facilities NextPlat served, and because that work carried exceptional margin, the loss was disproportionate.

A significant contributor to the decline in profitability was the permanent closure of a customer's medication fulfillment facility that we had previously served. Because that business carried particularly strong margins, its loss had a disproportionate impact on our profitability.

Birute Norkute, Healthcare Operations Executive · 2026-11-12
A single customer decision moved consolidated gross margin by roughly five points sequentially. The medication fulfillment facility relationship is high-margin and, evidently, not ownable. Meanwhile the legacy engine keeps shrinking. Retail prescription volume is below prior year on payer mix, lower reimbursement rates and clinics insourcing fulfillment as they grow — a pressure the broader market is living with too, which is why pharmacy reimbursement pressure surfaced high in the global keyword list this quarter. Management's answer is bolt-on density, and the pharmacy footprint expansion is now the company's single most-weighted theme: Scott's Pharmacy in Pensacola, closed 1 October for $1.5 million all-cash, guided to roughly $1.2 million of quarterly revenue and $150,000 of net profit in Q4, plus a new Jacksonville location. Against a $10.5 million quarterly revenue base, that is meaningful — and it is roughly four to five points of consolidated revenue growth that has to arrive just to hold the line.

The sentence that changed since May

Here is the tension worth carrying away. In May, asked directly why a company with cash and no debt had filed an at-the-market program, the CEO said: “we do not have any immediate plans to access the ATM, and I would add, wouldn't consider it at these current levels” — David Phipps · 2026-05-14. In November:

Also, during Q4, we began selling shares under the at-the-market program we established in May, raising over $140,000 in net proceeds.

Amanda Ferrio, Chief Financial Officer · 2026-11-12
$140,000 is rounding error against $11 million of effective net cash, and the balance sheet genuinely has no meaningful debt. But the size is the point: you do not tap an ATM for $140,000 because capital allocation is opportunistic. You tap it because you are funding a $1.5 million cash acquisition and a legal defense with a cash pile that has been halved since 2023. Cash fell sequentially to $11.2 million, which the CFO attributed to professional fees and public company expenses, and the same counsel-and-insurer language on the litigation has now appeared in three consecutive calls, unchanged. The global demand for satellite based connectivity segment, meanwhile, is the quiet cash generator: e-commerce revenue rose 3% year-on-year with flat 24% margins and record recurring airtime revenue, but sales fell about 6% sequentially into seasonal softness.

What is actually new

Three things, none of them 340B. Decathlon — the world's largest sporting goods retailer — is now selling an array of satellite connectivity products to online customers in 20 countries, with Mountain Warehouse and Easy Shop added in Europe. The healthcare e-commerce site slipped from end-of-Q3 to "this month," an admission worth noting given the site has been a headline promise for several quarters. And the automated dispensing kiosk is in transit for its first installation — a genuine strategic option, and one leaning into a theme the market is paying for: point of care has been a top-quartile advancing theme across diagnostics and hospital-service names over the last ninety days. It is the right direction, from a company with $19 million of market value, a stock that ran 45% in two weeks in late August and then gave back 19% into the print, and a still-negative operating income line whose improvement, on a sequential basis, stopped this quarter. The turnaround is real. It is also smaller than the adjectives.